Welcome to our dedicated page for Organon & Co. news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on Organon & Co. stock.
Organon & Co. (OGN) is a science-based global pharmaceutical company dedicated to developing and delivering essential health solutions. Founded in Oss, the Netherlands, Organon originally gained fame for pioneering the birth control pill, which revolutionized women's health. Over the years, the company expanded significantly and was acquired by Schering-Plough, and later by Merck, continuing its legacy as MSD in the Netherlands.
Today, Organon operates with a robust portfolio comprising women's health, biosimilars, and established medicines. The company focuses on providing prescription therapies that address a wide range of health needs, particularly in women's health. Organon's product offerings include innovations in contraception, fertility treatments, and menopause management.
In addition to women's health, Organon is committed to advancing the field of biosimilars - biologically similar products to existing branded drugs that promise to enhance patient access to key treatments. The company's established brands, which include a variety of well-known medications, continue to be a core revenue driver. Geographically, Organon derives most of its revenue from Europe and Canada, followed by the United States, and then the Asia Pacific and Japan regions.
Organon remains at the forefront of pharmaceutical innovation, driven by a mission to improve health outcomes globally. The company's strategic partnerships and continued investment in research and development reflect its commitment to addressing some of the most pressing health challenges of our time.
Accenture (NYSE: ACN) has partnered with Organon (NYSE: OGN) to transform the company’s enterprise resource planning (ERP) technology using SAP S4/HANA® on AWS. This collaboration aims to enhance the digital core of Organon, improving patient and employee experiences through real-time analytics and streamlined operations. The transition to a cloud-based platform is expected to minimize disruptions and support growth through efficient data management. Accenture’s expertise will help Organon navigate this modernization process effectively.
Organon reported Q3 2021 revenue of $1,600 million, down 1% from Q3 2020. Net income was $323 million or $1.27 per diluted share, a 42% decline year-over-year. Adjusted EBITDA fell 15% to $636 million, with a margin of 39.8%. The company affirmed its financial guidance and announced a quarterly dividend of $0.28 per share. Notably, Women’s Health revenue dropped 10%, while Biosimilars rose 41%. Organon is actively expanding through acquisitions and maintaining strong cash flow with $1,008 million in cash, despite high debt levels.
Organon (NYSE: OGN) has announced its acquisition of Forendo Pharma, a clinical-stage company focusing on innovative treatments for women’s health. The deal includes a $75 million upfront payment, with additional potential payments totaling up to $954 million based on milestones. Forendo's lead candidate, FOR-6219, is a novel oral HSD17B1 inhibitor for treating endometriosis and is entering Phase 2 clinical trials. This acquisition aligns with Organon’s commitment to addressing significant unmet needs in women's health, including conditions like endometriosis and polycystic ovarian syndrome (PCOS).
Organon (NYSE: OGN) will release its third quarter 2021 financial results on November 11, 2021, before a webcast and conference call at 8:30 a.m. ET. Interested parties can access the live call via the Organon website, with a replay available two hours post-event. Institutional investors must register in advance to participate. Formed from a spin-off of Merck (NYSE: MRK), Organon focuses on women's health with over 60 medicines and products, pursuing collaboration with biopharmaceutical innovators.
Organon (NYSE: OGN) has launched the Fertility Journey website to provide resources for individuals navigating fertility care. The initiative aims to educate users about infertility, treatment options, and emotional challenges. Statistics reveal that 7.3 million women utilized infertility services in the U.S. from 2006-2010. This launch coincides with the ASRM Scientific Congress in Baltimore (October 17-20), emphasizing Organon's commitment to enhancing fertility education.
Organon (NYSE: OGN) announced FDA clearance for its updated Jada® System, designed to treat abnormal postpartum uterine bleeding effectively. Postpartum hemorrhage cases have risen significantly in the U.S. The updated system features a new kit configuration and improved ease of use, enhancing treatment options in maternal health. The reconfigured Jada system is set to be available in January 2022. This strategic move follows Organon's acquisition of Alydia Health, reinforcing its commitment to women's health.
Organon (NYSE: OGN) has launched a Public Service Announcement (PSA) aimed at raising awareness about the high rates of unplanned pregnancies globally, affecting approximately 121 million women each year. Despite progress in reproductive health, many women still lack access to modern contraceptive methods. The initiative encourages conversations around reproductive well-being and invites participation from women, families, and healthcare professionals. The PSA will be aired across local television and social media channels.
Organon (NYSE: OGN) announced that CEO Kevin Ali and CFO Matthew Walsh will participate in a fireside chat at Morgan Stanley's 19th Annual Global Healthcare Virtual Conference on September 13, 2021, at 9:30 a.m. EDT. Investors and the public can access the live webcast at Organon Events. Organon focuses on women's health and has over 60 products, including reproductive health and biosimilars. The company aims to invest in growth opportunities and collaborate with biopharmaceutical innovators.
Organon (NYSE: OGN) will participate in a fireside chat at Citi’s 16th Annual BioPharma Virtual Conference on September 10, 2021, at 9:45 a.m. EDT. The session will feature CEO Kevin Ali and CFO Matthew Walsh. Investors, analysts, and the public are encouraged to view the live webcast here.
Organon focuses on women's health, offering over 60 products across various therapeutic areas, and recently acquired Alydia Health, specializing in postpartum hemorrhage. The company is headquartered in Jersey City, New Jersey.
Avestria Ventures, a venture capital firm based in the San Francisco-Bay Area, has successfully closed its Fund I aimed at investing in early-stage women’s health and female-led life sciences companies.
Founded by Linda Greub and Corinne Nevinny, Avestria targets sectors traditionally underserved by venture capital, with less than 1% of the $4T US healthcare market focused on women’s health as of 2020. Notable achievements include the June acquisition of portfolio company Alydia Health by Organon (NYSE: OGN) for up to
FAQ
What is the current stock price of Organon & Co. (OGN)?
What is the market cap of Organon & Co. (OGN)?
What is Organon & Co. known for?
What are the main product areas of Organon & Co.?
Where does Organon & Co. generate most of its revenue?
Who previously acquired Organon & Co.?
What types of products does Organon offer in women's health?
What are biosimilars?
How does Organon & Co. contribute to global health?
Has Organon & Co. been involved in any recent significant projects or initiatives?
What is the history of Organon & Co. in the Netherlands?
What is the significance of Organon's established brands?
